ArticleBMC cancer2025
Expression of CD73 and VEGF in salivary gland carcinomas: associations with clinicopathological characteristics in Vietnamese population.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tissue Homogenate VEGF Levels in Malignant Salivary Gland Tumors vs. Controls: An Exploratory Pilot Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalivary gland carcinoma is a rare malignancy with diverse histological subtypes and poor prognosis, particularly when diagnosed at advanced stages. Recent evidence suggests that biomarkers such as CD73 and VEGF may play important roles in tumor progression and immune evasion, yet limited studies have evaluated their expression and clinical significance in Southeast Asian populations. This study aimed to determine the expression rates of CD73 and VEGF in salivary gland carcinoma and identify clinicopathological factors associated with their expression in a Vietnamese patient cohort.
methodsA retrospective study was conducted on 111 salivary gland carcinoma patients who underwent surgical treatment in Ho Chi Minh City, Vietnam. Immunohistochemical analysis of CD73, VEGF, and Ki-67 expression was performed on paraffin-embedded tumor samples. Logistic regression models were used to identify factors independently associated with biomarker expression.
resultsCD73 and VEGF were expressed in 53.2% and 66.7% of salivary gland carcinoma cases, respectively. CD73 expression was significantly associated with female gender (OR = 2.74, 95% CI 1.07-7.01), tumor stage T2 (OR = 6.59, 95% CI 1.36-31.90) and T4 (OR = 9.13, 95% CI 1.68-49.66), mucoepidermoid carcinoma subtype (OR = 10.62, 95% CI 2.77-40.69), and higher Ki-67 levels (OR = 3.61 per 10% increase, 95% CI 1.26-10.31). In contrast, lymph node level N2 was inversely associated with CD73 (OR = 0.08, 95% CI 0.01-0.70). VEGF expression was independently more likely in patients with normal body mass index compared to those who were overweight or obese (OR = 0.30 for overweight/obese vs. normal, 95% CI 0.12-0.78), and was also associated with increased Ki-67 expression (OR = 2.95, 95% CI 1.09-7.99).
conclusionsHigh expression rates of CD73 and VEGF suggest their potential as prognostic biomarkers and therapeutic targets in salivary gland carcinoma. Their associations with tumor stage, histology, BMI, and proliferation index (Ki-67) highlight the need for further research on personalized treatments. These findings provide important insights into biomarker expression in Vietnamese salivary gland carcinoma patients and lay the groundwork for biomarker-driven therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.